Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATC rebounding: +184%
At own peril this one :)
Ah, k, makes sense indeed.
PRGN: +22% on lender agreement news
ONCY: +50%
How'd I miss that...
AAPL -1.5% GOOG +2%
GOOG up on news its maps are available on AAPL again.
No real reaction yet, let's see what the opening bell brings.
Sounds like decent news to me.
Prana's PBT2 benefits on Huntington's Disease published
Prana Biotechnology announced that the Journal of Huntington's Disease has, in its December edition, published data showing the benefits of PBT2 in Huntington Disease. The paper describes PBT2's ability to inhibit the development of the symptoms and pathological features of Huntington Disease in pre-clinical transgenic animal models
No YGE, $F?
Thx for the list, BTW :)
RIGL -32% now
Had to go back years to find similar levels.
Wow, look at FSLR jumping from 8:30 on. Plenty of momo here now.
BTW, SOL in the end was one of the best solar performers. Not sure if it was mentioned a lot yesterday.
Agree, and this stock has shown it can be tricky.
Currently oscillating between 2.27 and 2.59.
DHRM receives software copyrights for DHR C-Arm X Ray machine
Dehaier Medical announced that it has obtained Megapixels software copyrights for its DHR C-Arm X Ray Machine. The application enhances the Dehaier's DHR C-Arm X Ray Machine, by offering improved image quality and easier image acquisition to strengthen the customer experience. The software can also help to improve patient management, increase ease of use and image processing for users. The upgraded C-Arm X Ray Machine can produce optimized images with minimal user involvement through its advanced imaging technology
U.S. federal agency to test RIM's BlackBerry 10
Research In Motion said a U.S. federal agency, which recently outlined plans to move away from BlackBerry in favor of Apple Inc's iPhone, is now set to begin testing RIM's new BlackBerry 10 platform and devices.
The U.S. Immigration and Customs Enforcement agency (ICE), will early next year begin a pilot program on RIM's new line of BlackBerry 10 smartphones and BlackBerry Enterprise Service 10 (BES 10), which allows corporations and government users to run the new devices on their networks, a RIM spokeswoman said late on Wednesday.
http://finance.yahoo.com/news/u-federal-agency-test-rims-051750290.html
Spectrum's Zevalyn, Fotolyn and Belinostat show positive clinical data
http://news.yahoo.com/spectrum-pharmaceuticals-highlights-promising-zevalin-120000287.html
BBY & Schulze again
I thought this was done, guess it's not:
http://www.startribune.com/business/183278681.html
Brilliant summary in between all the fiscal cliff BS yapping.
A bio will always be a bio, I guess. At least we have that out of the way.
A 4% gain and we're over the 200MA, let's see what gives.
Suntech and SunSystem announce 25 MW sales agreement in Romania
WUXI, China, Dec. 13, 2012 /PRNewswire/ -- Suntech Power Holdings Co., Ltd. (NYSE: STP), one of the world's largest producers of solar panels, and SunSystem S.p.A., a leading Italian solar engineering, procurement and construction (EPC) company, have signed a contract for Suntech to supply 25 megawatts (MW) of polycrystalline solar panels. The Suntech solar panels will power two new photovoltaic projects under construction in Romania that will be grid connected by the end of 2013.
"We are pleased to collaborate with SunSystem, a leading EPC company in Italy and Romania. Suntech's collaboration with SunSystem marries global expertise with best practices to deliver reliable and cost-effective solar to Romanian communities," said Vincenzo Quintani, South-East Europe Sales Director, Suntech. "This project, along with our recent contract with EDP Renovaveis, underscores the viability of our growth strategy in Eastern Europe."
http://www.streetinsider.com/Press+Releases/Suntech+and+SunSystem+Announce+25MW+Sales+Agreement+in+Romania/7945100.html
QLGC is a bit of a laggard ATM. Some insider buying would help.
As for FITB: don't usually do bank, how'd you end up there? Technicals?
I remember this one stalling a while back, with some nasty games being played. Plenty of resistance here, the more insider buying, the better.
Nice :)
Should appreciate a bit more, I got mid 14s in mind, others say a top at $15. Either way, above your strike price.
BBY had some interesting AH trading. Seeing news of Form 4 but that seems to have been reported after the rush.
http://www.secform4.com/filings/764478/000122520812025138.htm
TELK: +33% AH
Another bio with news, tomorrow should be fun - again.
Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology
PALO ALTO, Calif., Dec. 12, 2012 /PRNewswire/ -- Telik, Inc. (TELK) announced today the publication of a clinical trial abstract in the proceedings of the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. The abstract, "Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by Roger M. Lyons, MD; Sharon T. Wilks, MD; and of David J. Friedman MD, PhD, of Cancer Care Centers of South Texas, US Oncology in San Antonio, Texas; and Shelby A. Young, RN, BSN, and Gail L. Brown, MD, of Telik, Inc., in Palo Alto, California, is available online at Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4394.
This abstract reports the preliminary results of a clinical trial with ezatiostat to study the treatment of patients with idiopathic chronic neutropenia (ICN). ICN is a rare group of blood disorders characterized by low circulating neutrophils, recurrent fevers, mucosal inflammation and serious systemic infections. The risk and severity of these complications is related to abnormally low levels of white blood cells. Most patients initially respond to treatment with granulocyte colony stimulating factors (G-CSF); however, some patients fail to respond or become resistant to G-CSF treatments. Further, G-CSF therapy is often associated with bone and muscle pain, low platelet counts and enlargement of the spleen. Patients may need to be on G-CSF for the rest of their lives, and these side effects can interfere with therapy.
http://finance.yahoo.com/news/telik-announces-telintra-clinical-publication-212000117.html
EXEL another +3%
Still on track.
We trust that block?
Awfully quiet in pinky land, a few honest companies now making the waves. The world must be coming to an end.
They must be lacking the fire power, or not really feeling it this late in the year :)